Management of Sickle Cell Intrahepatic Cholestasis: An Argument in Favor of Automated Exchange Transfusion
Sickle cell disease patients are commonly treated at transfusion medicine services, and understanding of the hepatic manifestations of the disease is key for optimal management, specifically, in individuals presenting with sickle cell intrahepatic cholestasis (SCIC). SCIC represents a rare, severe h...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAABRON PRESS
2019-09-01
|
| Series: | Clinical Hematology International |
| Subjects: | |
| Online Access: | https://www.atlantis-press.com/article/125912325/view |
| _version_ | 1827298298241744896 |
|---|---|
| author | Brian D. Adkins Bipin N. Savani Garrett S. Booth |
| author_facet | Brian D. Adkins Bipin N. Savani Garrett S. Booth |
| author_sort | Brian D. Adkins |
| collection | DOAJ |
| description | Sickle cell disease patients are commonly treated at transfusion medicine services, and understanding of the hepatic manifestations of the disease is key for optimal management, specifically, in individuals presenting with sickle cell intrahepatic cholestasis (SCIC). SCIC represents a rare, severe hepatic crisis wherein sinusoidal red cell sickling leads to massive hepatocyte dysfunction and cholestatic laboratory findings. Acute SCIC is defined by abdominal pain with progressive hepatic injury associated with hyperbilirubinemia, renal failure, encephalopathy, and coagulopathy. Patients are generally managed with red blood cell exchange transfusion (RBCEx), when available, as this is a potentially fatal condition. Simple transfusion may be utilized in resource-poor environment or when patients refuse RBCEx. As less than 50 adult cases have been described in the literature, many of them with limited follow-up, randomized clinical trials comparing RBCEx with other treatments are currently unfeasible. Likewise, a chronic form exists, but is less well characterized, and is associated with persistent bilirubinemia and a variable course in terms of progressive hepatic disease. We undertake a brief review of the literature and discuss two cases of SCIC managed with RBCEx at our institution. |
| first_indexed | 2024-04-24T15:11:47Z |
| format | Article |
| id | doaj.art-7d4839d393aa4e86be2ba3f84dc4251f |
| institution | Directory Open Access Journal |
| issn | 2590-0048 |
| language | English |
| last_indexed | 2024-04-24T15:11:47Z |
| publishDate | 2019-09-01 |
| publisher | SAABRON PRESS |
| record_format | Article |
| series | Clinical Hematology International |
| spelling | doaj.art-7d4839d393aa4e86be2ba3f84dc4251f2024-04-02T10:47:08ZengSAABRON PRESSClinical Hematology International2590-00482019-09-011310.2991/chi.d.190630.001Management of Sickle Cell Intrahepatic Cholestasis: An Argument in Favor of Automated Exchange TransfusionBrian D. AdkinsBipin N. SavaniGarrett S. BoothSickle cell disease patients are commonly treated at transfusion medicine services, and understanding of the hepatic manifestations of the disease is key for optimal management, specifically, in individuals presenting with sickle cell intrahepatic cholestasis (SCIC). SCIC represents a rare, severe hepatic crisis wherein sinusoidal red cell sickling leads to massive hepatocyte dysfunction and cholestatic laboratory findings. Acute SCIC is defined by abdominal pain with progressive hepatic injury associated with hyperbilirubinemia, renal failure, encephalopathy, and coagulopathy. Patients are generally managed with red blood cell exchange transfusion (RBCEx), when available, as this is a potentially fatal condition. Simple transfusion may be utilized in resource-poor environment or when patients refuse RBCEx. As less than 50 adult cases have been described in the literature, many of them with limited follow-up, randomized clinical trials comparing RBCEx with other treatments are currently unfeasible. Likewise, a chronic form exists, but is less well characterized, and is associated with persistent bilirubinemia and a variable course in terms of progressive hepatic disease. We undertake a brief review of the literature and discuss two cases of SCIC managed with RBCEx at our institution.https://www.atlantis-press.com/article/125912325/viewSickle cell hepatopathySickle cell diseaseApheresisRed blood cell exchangeExchange transfusion |
| spellingShingle | Brian D. Adkins Bipin N. Savani Garrett S. Booth Management of Sickle Cell Intrahepatic Cholestasis: An Argument in Favor of Automated Exchange Transfusion Clinical Hematology International Sickle cell hepatopathy Sickle cell disease Apheresis Red blood cell exchange Exchange transfusion |
| title | Management of Sickle Cell Intrahepatic Cholestasis: An Argument in Favor of Automated Exchange Transfusion |
| title_full | Management of Sickle Cell Intrahepatic Cholestasis: An Argument in Favor of Automated Exchange Transfusion |
| title_fullStr | Management of Sickle Cell Intrahepatic Cholestasis: An Argument in Favor of Automated Exchange Transfusion |
| title_full_unstemmed | Management of Sickle Cell Intrahepatic Cholestasis: An Argument in Favor of Automated Exchange Transfusion |
| title_short | Management of Sickle Cell Intrahepatic Cholestasis: An Argument in Favor of Automated Exchange Transfusion |
| title_sort | management of sickle cell intrahepatic cholestasis an argument in favor of automated exchange transfusion |
| topic | Sickle cell hepatopathy Sickle cell disease Apheresis Red blood cell exchange Exchange transfusion |
| url | https://www.atlantis-press.com/article/125912325/view |
| work_keys_str_mv | AT briandadkins managementofsicklecellintrahepaticcholestasisanargumentinfavorofautomatedexchangetransfusion AT bipinnsavani managementofsicklecellintrahepaticcholestasisanargumentinfavorofautomatedexchangetransfusion AT garrettsbooth managementofsicklecellintrahepaticcholestasisanargumentinfavorofautomatedexchangetransfusion |